Galderma Research & Development

Catherine Raffin

Philippe Diaz

Thibaud Biadatti

Novel compounds that are modulators of PPAR-type receptors having the structural formula (I): are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine (in dermatology, and in the field of cardiovascular diseases, immune diseases and/or diseases linked to the metabolism of lipids), or, alternatively, into cosmetic compositions.

Modulators of the PPAR-type receptors and pharmaceutical/cosmetic applications thereof

Novel ligand antagonists of the RAR receptors have the following structural formula (I): in which A is a CH, CHOH, C&#x2550;O or C&#x2550;N&#x2014;OH radical or a sulfur or selenium atom; B is a radical selected from among those of formulae (a) to (f): and Ar is a radical selected from among those of formulae (g) to (i): 

Growing community of inventors

Antibes, France

Catherine Raffin